Log in

NASDAQ:DTIL - Precision BioSciences Stock Price, Forecast & News

+0.15 (+2.48 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $6.19
50-Day Range
MA: $7.34
52-Week Range
Now: $6.19
Volume298,393 shs
Average Volume498,285 shs
Market Capitalization$318.17 million
P/E RatioN/A
Dividend YieldN/A
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:DTIL



Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share


Net Income$-92,880,000.00
Net Margins-417.65%


Market Cap$318.17 million
Next Earnings Date5/4/2020 (Estimated)
OptionableNot Optionable

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DTIL stock has decreased by 4.6% and is now trading at $6.19. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Precision BioSciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Precision BioSciences.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Precision BioSciences.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences Inc (NASDAQ:DTIL) posted its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.15. The business had revenue of $6.52 million for the quarter, compared to the consensus estimate of $9.56 million. Precision BioSciences had a negative return on equity of 66.96% and a negative net margin of 417.65%. View Precision BioSciences' earnings history.

What price target have analysts set for DTIL?

8 analysts have issued 12 month price targets for Precision BioSciences' shares. Their forecasts range from $19.00 to $24.00. On average, they anticipate Precision BioSciences' share price to reach $22.17 in the next twelve months. This suggests a possible upside of 258.1% from the stock's current price. View analysts' price targets for Precision BioSciences.

What are Wall Street analysts saying about Precision BioSciences stock?

Here are some recent quotes from research analysts about Precision BioSciences stock:
  • 1. According to Zacks Investment Research, "Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Our $21 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our 13-year DCF model. Our DCF is based on: beta of 1.6, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.5%, and tax rate of 15% beginning in FY 2028. Our $21 price target remains leveraged on the outcome of for which we assign a 25% and 10% POS, respectively, given their IND-ready status. These two assets represent approximately 73% of our rNPV, i.e., $15 per share." (7/16/2019)

Has Precision BioSciences been receiving favorable news coverage?

Press coverage about DTIL stock has been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Precision BioSciences earned a news sentiment score of -3.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutPrecision BioSciences.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,957,900 shares, an increase of 18.7% from the February 27th total of 1,650,000 shares. Based on an average daily volume of 519,100 shares, the days-to-cover ratio is currently 3.8 days. Currently, 5.8% of the company's shares are sold short. View Precision BioSciences' Current Options Chain.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Alibaba Group (BABA), Exxon Mobil (XOM), Alector (ALEC), NVIDIA (NVDA), Gilead Sciences (GILD), Gossamer Bio (GOSS), Immunomedics (IMMU), Inovio Pharmaceuticals (INO) and Micron Technology (MU).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 42)
  • Dr. Derek Jantz Ph.D., Co-founder, Chief Scientific Officer & Director (Age 43)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 41)
  • Ms. Molly Lukes PHR, SHRM-CP, Director of HR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital World Investors (8.00%), FMR LLC (5.18%), ArrowMark Colorado Holdings LLC (3.83%), Alliancebernstein L.P. (3.01%), Franklin Resources Inc. (2.39%) and Franklin Resources Inc. (2.39%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao. View institutional ownership trends for Precision BioSciences.

Which institutional investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Franklin Resources Inc., Hamilton Lane Advisors LLC, and Barclays PLC. View insider buying and selling activity for Precision BioSciences.

Which institutional investors are buying Precision BioSciences stock?

DTIL stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Alliancebernstein L.P., ArrowMark Colorado Holdings LLC, Adams Chetwood Wealth Management LLC, State Street Corp, Victory Capital Management Inc., Victory Capital Management Inc., and Nachman Norwood & Parrott Inc. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao. View insider buying and selling activity for Precision BioSciences.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $6.19.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $318.17 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 127 workers across the globe. View additional information about Precision BioSciences.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is http://www.precisionbiosciences.com/.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

MarketBeat Community Rating for Precision BioSciences (NASDAQ DTIL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  57 (Thanks for Voting!)
Underperform Votes:  36 (Thanks for Voting!)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about Precision BioSciences and other stocks. Vote "Outperform" if you believe DTIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DTIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel